Ascendis Pharma A/S (FRA:A71)

Market Cap	11.56B +37.8%
Revenue (ttm)	720.13M +98.0%
Net Income	-228.03M
EPS	-3.76
Shares Out	n/a
PE Ratio	n/a
Forward PE	39.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	190.00
Previous Close	189.00
Day's Range	190.00 - 190.00
52-Week Range	122.00 - 210.00
Beta	n/a
RSI	45.66
Earnings Date	Apr 30, 2026

About Ascendis Pharma

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 1,189
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: A71

Financial Performance

In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.